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Functional analysis of Fas signaling in vivo using synthetic
inducers of dimerization
David M. Spencer*†, Peter J. Belshaw‡, Lei Chen*, Steffan N. Ho*, Filippo
Randazzo*§, Gerald R. Crabtree* and Stuart L. Schreiber‡
Background: Genetic abnormalities in the Fas receptor or its trimeric ligand,
FasL, result in massive T-cell proliferation and a lupus-like autoimmune syndrome,
which was initially attributed to excessive lymphoproliferation but is now ascribed
to the absence of Fas-mediated cell death. Although Fas is normally expressed
on most thymocytes, negative selection seems to be unperturbed in Fas-
deficient (lpr) mice. This suggests that Fas has an important function in
peripheral, but not thymic, T cells.
Results: To explore the Fas-mediated cell death pathway both in vitro and in
vivo, we used conditional alleles of the Fas receptor that can be triggered by an
intracellularly active chemical inducer of dimerization known as FK1012. We
found that membrane attachment is important for Fas function and, unlike
previous results with anti-Fas monoclonal antibodies, we show that dimerization
is sufficient to trigger apoptosis. Finally, the administration of FK1012 in vivo to
transgenic animals expressing the conditional Fas receptor in thymocytes
demonstrates that sensitivity to Fas-mediated apoptosis is restricted to
CD4+ CD8+ thymocytes.
Conclusions: Here, we describe the first in vivo application of non-toxic, cell-
permeable synthetic ligands to regulate signal transduction in transgenic mice
expressing a conditional receptor. Using this system, we show that the Fas
pathway is restricted to double-positive thymocytes in vivo, consistent with
recent in vitro findings with thymocytes. This method promises to be useful not
only for developmental studies involving cell ablation, but also for studies
involving the regulation of a wide variety of signaling molecules.
Background
The formation and homeostasis of tissues is regulated by
the two opposing processes of proliferation and pro-
grammed cell death. This is particularly evident in the
developing immune system, in which thymocytes capable
of reacting with foreign antigens must be selected from a
large reservoir of cells with distinct reactivities, while
potentially autoreactive or hyporeactive thymocytes must
be eliminated. Similarly, in peripheral lymphoid tissue,
previously activated, but ultimately obsolete, lymphocytes
must be expeditiously removed from the circulation to
provide space for T cells with new specificities.
A requisite role for cell-surface receptors in regulating pro-
grammed cell death or activation-induced cell death in T
cells was established, in part, by the identification of the
cell-surface receptor Fas (also called APO-1) in screens for
cytolysis-inducing monoclonal antibodies [1–3]. Fas
crosslinking usually leads to a form of programmed cell
death, termed apoptosis, which is characterized by con-
densation of the cell, membrane blebbing, segmentation
of the nucleus and internucleosomal DNA degradation
[4]. Fas is a member of a growing family of receptors
which are similar in their ‘cysteine-rich’ extracellular
domains; these include NGFR (the low-affinity receptor
for nerve growth factor), TNFRI and TNFRII (the type I
and type II receptors for tumour necrosis factor), CD40,
OX40, CD30 and CD27 (reviewed in [5]). The intracellu-
lar ‘signaling’ domain of Fas, however, only shares homol-
ogy with a subset of these receptors, including TNFRI,
NGFR and a growing subset of TNFRI- and Fas-associ-
ated proteins (FAPs) (reviewed in [6]). In each case, the
cytoplasmic homology maps to a conserved ‘death domain’
which has been shown to be necessary for the cytolytic
character of each receptor or signaling molecule [6–8].
The nickname ‘death domain’, however, appears to be a
misnomer, and rather than providing cytolytic functions it
may actually serve as a protein–protein interaction motif
for recruiting FAPs. The molecular mechanism(s) by
which FAPs couple to downstream signaling cascades has
not yet been determined.
Naturally occurring Fas mutations provided initial insights
into the role of Fas-mediated apoptosis in development
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[9,10]. Although Fas is normally expressed in a variety of
tissues — including the thymus, liver, lungs and ovaries —
and in activated B and T cells [1,3], mutations in Fas (lpr
and lprcg [11,12]) cause phenotypic changes only in
hematopoietic cells. (Genetic ablation of Fas also leads to
substantial liver hyperplasia [13].) It has been found that
lpr/lpr mice exhibit a pronounced lymphadenophathy with
excessive numbers of unusual CD4– CD8– (double-
negative) B220+ T cells. These mice also have an auto-
immune disorder that is related to systemic lupus
erythematosus and is characterized by increased levels of
T-cell dependent autoantibodies (reviewed in [9]). These
observations led to the model that the normal function of
Fas is in the deletion of autoreactive T and B cells [14].
Analysis of Fas expression and signaling during a normal
immune response suggested an even broader role for Fas.
The Fas protein is induced in resting, peripheral T cells
within 24 hours after antigen stimulation in vitro, although
susceptibility to Fas-mediated death takes several days
[15,16]. This transition correlates with expression of the
Fas ligand, FasL, which has been shown to be necessary
for activation-induced cell death (reviewed in [17]). Thus,
the antigen receptor controls the expression of Fas and its
ligand, and their coexpression leads to cell death. However,
during the ‘latency’ period, crosslinking of surface-bound
Fas with anti-Fas monoclonal antibodies or with FasL does
not trigger apoptosis, implying that some developmentally
regulated restriction to Fas signaling also exists.
Whether Fas signaling is required during thymocyte
ontogeny remains unclear. Fas is expressed [18] and func-
tional [19] in the majority of immature CD4+ CD8+
(double-positive) thymocytes, concomitant with thymic
selection. Deletion of potentially autoreactive thymocytes,
however, seems to proceed normally in lpr mice (which
are deficient in Fas) and in gld mice (which are deficient
in FasL), indicating that Fas is probably not essential for
normal thymic development (reviewed in [9]). Further-
more, FasL does not seem to be expressed at significant
levels in the thymus [20]. Nevertheless, because early
thymectomy (less than 2 weeks postpartum) alleviates the
lpr defect [21], a mitigating role for thymus-derived cells
in the disease process must exist. The work of Mountz
and colleagues [22] offers one resolution by suggesting
that although positive and negative selection may proceed
normally in lpr mice, otherwise ‘neglected’ TCRlo thymo-
cytes are the true thymic targets of Fas signaling and may
be the precursors of the peripherally expanded T cells.
In order to clarify the role of Fas during thymic develop-
ment, and to further elucidate the molecular details of Fas
signaling, we have developed a means of artificially acti-
vating Fas receptor functions by bypassing its natural
ligand through the use of a cell-permeable synthetic
ligand called FK1012 [23]. Although FasL is apparently
trimeric in solution [24] and anti-APO-1 F(ab′)2 fragments
are incapable of triggering apoptosis in vitro [25], we find
that the simple dimerization of two Fas domains can
trigger apoptosis. Finally, because FK1012 permeates
cells, we were able to study the ability of the conditional
Fas receptor to trigger apoptosis in transgenic mice. These
studies revealed that double-positive thymocytes are par-
ticularly sensitive to Fas-mediated apoptosis. This system
should ultimately permit analysis of the role of Fas in a
temporally controlled fashion in various tissues, and help
to elucidate its role in the B- and T-cell abnormalities of
the Fas-deficient mice and in autoimmunity.
Results
FK1012 induces death in lymphocytes expressing the
Fas–FKBP fusion protein
To determine the function of Fas during thymic develop-
ment and to explore signaling mechanisms we used
FK1012 to artificially activate Fas [23]. We constructed
plasmids that encoded chimeric proteins which contained
the cytoplasmic domain of Fas adjacent to one or more
tandem copies of the FK1012-binding protein (FKBP),
the myristoylation-targeting peptide (M) from the amino
terminus of v-src, and the influenza hemagglutinin (HA)
epitope (E) (Fig. 1a,b). The encoded proteins were desig-
nated M–Fas–FKBPn–E.
To determine the signaling capacity of M–Fas–FKBPn–E,
an expression vector, pM/Fas/FKBP3/E-neo, containing
the neomycin resistance gene, was electroporated into
D10.11 T cells. Initially, G418-resistant clones were
selected and screened for responsiveness to 500 nM
FK1012. In two clones, D10#10 and D10#20, 100 % of the
cells died after incubation with FK1012. Both clones
expressed the chimeric construct, as determined by
western-blot analysis (data not shown).
To determine whether death was due to necrosis or apop-
tosis, clone D10#10 was treated for several hours with
250 nM FK1012 and compared with the identically treated
parental line (Fig. 1c,d). Although both lines were initially
95–100 % viable, within 4 hours, pyknotic nuclei and mem-
brane disintegration were prevalent in clone D10#10,
whereas the parental line looked normal. Even within
1 hour, pyknotic nuclei and membrane blebbing were
detectable in clone D10#10 (data not shown). The LC50 for
death by FK1012 in D10#10 cells was ~15 nM; in contrast,
the monomeric FK506-derivative, FK506-M [23], was inert
at concentrations up to 1 mM, indicating that crosslinking
was required for programmed cell death (data not shown).
Internucleosomal chromosomal degradation also appeared
promptly after FK1012 treatment in clones D10#10 and
D10#20, but was not visible in the parent line (Fig. 1e).
Even after several days of treatment, 250 nM FK1012 had
no effect on the viability of the parent D10.11 or on 
other cell lines (data not shown). Thus, FK1012-mediated
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intracellular crosslinking of the membrane-tethered cyto-
plasmic domain of Fas results in apoptosis in T cells,
providing a useful tool to dissect Fas-mediated signaling.
Fas dimerization is sufficient for signaling in Jurkat T cells
Although structural features of soluble trimeric FasL
suggest that signaling by the Fas receptor might occur by
homotrimerization [24], experimental evidence that multi-
merization is essential is based solely on crosslinking with
antibodies [25,26]. The approach based on the use of the
chemical inducer of dimerization permitted a reanalysis of
this question, and allowed the extent of crosslinking to be
controlled by the number of FKBP dimerization domains
attached to Fas. For these experiments, Fas-mediated
apoptosis of transiently transfected cells was assayed by
flourescence-activated cell sorting (FACS) analysis (Fig. 2).
To study the requirements for Fas signaling, plasmids
encoding various Fas–FKBP fusion proteins containing
1–3 copies of FKBP12 were transiently transfected into
Jurkat-TAg T cells along with a plasmid expressing a trun-
cated signaling-deficient CD8a surface marker. After
24 hours, CD8a bright cells (2–2.5 % of total) were sorted
by FACS and divided into two aliquots. One aliquot was
mock-treated (Fig. 2a,c,e) and the other was treated with
1 mM FK1012 (Fig. 2b,d,f). After an additional 16 hours,
cells were analyzed for viability (Fig. 2a–g).
Although FK1012 had no effect on the viability of control
cells expressing M–FKBP3 (Fig. 2a,b) or on controls
expressing the mutant Fas receptor (based on lprcg [11])
M–Fas-cg–FKBP3 (Fig. 2g), FK1012 induced nearly com-
plete apoptosis in cells expressing the myristoylated
M–FKBP3–Fas proteins (compare Fig. 2c with 2d) or
M–Fas–FKBP3 (in which the order of Fas and FKBP3 was
reversed; data not shown). Surprisingly, even when only a
single FKBP was fused to the Fas signaling domain, a sig-
nificant degree of apoptosis was still observed (Fig. 2g).
Western blotting of extracts from unsorted, transiently
transfected cells demonstrated that the attachment of Fas
to the membrane was slightly cytotoxic and consistently
led to a 2–3 fold decrease in protein expression. Therefore,
the non-myristoylated fusion proteins, DM–FKBP1–Fas
and DM–FKBP3–Fas and M–Fas-cg–FKBP3, were consis-
tently expressed at higher levels. However, variation of the
number of copies of FKBP had little, if any, effect on the
expression of myristoylated M–FKBPn–Fas (data not
shown). Therefore, FK1012-mediated crosslinking of Fas
is sufficient to induce apoptosis.
Membrane tethering of Fas is essential for triggering
apoptosis
A number of cytoplasmic proteins containing death
domains have recently been identified [6]. Although their
roles in apoptosis are still undefined, the formal possibil-
ity exists that the membrane-independent aggregation of
one or more of these proteins is sufficient to trigger apop-
tosis. Because FK1012 is cell-permeable, we were able to
investigate whether signaling by a death domain-contain-
ing protein requires its association with the membrane.
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Figure 1
The effect of FK1012 on T cells that express M–Fas–FKBP3. (a) Model
of a conditional Fas receptor. FK1012 diffuses across the plasma
membrane and effects the crosslinking of a myristoylated cytoplasmic
domain of Fas, leading to Fas signaling. (b) Schematic of the plasmid
encoding the myristoylated receptor Fas–FKBP. M, myristoylation
targeting peptide from v-src (residues 1–14) [13]; Fas, the cytoplasmic
domain of Fas (residues 179–319) [1]; Ep, influenza HA epitope. C,
SacII; X, XhoI; S, SalI; E, EcoRI; S–X or X–S represent SalI–XhoI
ligations, which eliminate both sites. D10.11 cells (c) or D10#10 cells
(d) expressing M–Fas–FKBP3–E were treated for 4 h with 250 nM
FK1012A and photographed by phase-contrast microscopy. (e)
D10.11, D10#10 or D10#20 cells were treated for 0 h (lanes 2,5 and
8), 1 h (lanes 3,6 and 9) or 2 h (lanes 4,7 and 10) with 250 nM
FK1012. Genomic DNA was isolated and separated on a 1.8 %
agarose gel. Markers (lane 1) are from HaeIII-digested fX174 RF DNA.
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Mutation of the amino-terminal glycine residue of the
chimeric Fas constructs disrupts myristoylation, thereby
preventing membrane binding [27,28]. In contrast to the
results with membrane-tethered Fas, FK1012 did not
trigger apoptosis in cells expressing the non-myristoylated
DM–FKBP3–Fas protein (compare Fig. 2e,f with 2c,d); the
concentrations of FK1012 used were well in excess of the
LC50 for cells expressing myristoylated Fas. Similar results
were achieved when the incubation period with FK1012
was extended to 24 hours (data not shown).
To ensure that proteins not associated with the membrane
were expressed efficiently, Fas–FKBP expression in tran-
siently-transfected Jurkat cells was analyzed by western
blotting and by confocal microscopy using the anti-HA
antibody, 12CA5. Although myristoylated M–FKBP1–Fas
was primarily localized at the plasma membrane and
apparently excluded from the nucleus (Fig. 2h), non-
myristoylated DM–FKBP1–Fas was distributed through-
out the cell, including the nucleus (Fig. 2i). This
demonstrated that although comparable amounts of
DM–FKBP1–Fas were expressed, as determined by confo-
cal microscopy (Fig. 2h,i) and western blotting (data not
shown), membrane attachment of Fas was required to
trigger apoptosis.
Fas signaling leads to the ablation of CD4+ CD8+ thymocytes
To test the ability of a Fas–FKBP fusion protein to trigger
apoptosis in primary thymocytes, we produced transgenic
mice expressing M–FKBP2–Fas under the influence of
the Lck proximal promoter [29]. We chose to study a
representative mouse line (#8), which expressed easily
detectable levels of the transgene product. The ability of
FK1012 to induce apoptosis in vitro was compared to that
of the corticosteroid dexamethasone, by using FACS
analysis based on propidium iodide exclusion. Although
dexamethasone elicited apoptosis in the majority (~80 %)
of thymocytes from both wild-type and transgenic mice
after a 20 hour incubation, FK1012 triggered ~75 % apop-
tosis only in transgenic thymocytes (data not shown).
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Figure 2
The crosslinking and membrane-association
requirements for FK1012-dependent
apoptosis by M–FKBPn–Fas. (a–f) Jurkat-TAg
cells were cotransfected with an expression
vector, pCA28D1, which encoded a truncated
(cytoplasmic domain deleted) CD8a, along
with plasmids expressing either myristoylated
(M) FKBP (M–FKBP3) (a,b), M–FKBP3–Fas
(c,d), or non-myristoylated (DM) FKBP3–Fas
(e,f) expression vectors. Transfected cells
were mechanically sorted by FACS using
phycoerythrin (PE)-labeled anti-CD8a
antibodies and incubated for 18 h in complete
media (a,c,e) or complete media containing
1 mM FK1012 (b,d,f). The percentages
represent the fraction of the total cells sorted
that fall within the designated gates, chosen to
represent the majority (>95 %) of viable cells
in a control, untreated sample. (g) Cells were
transfected as above with plasmids encoding
a variety of myristoylated and non-
myristoylated Fas–FKBPn fusion proteins, or
with control plasmids expressing M–FKBPn
containing 1–3 copies of FKBP. The
constructs used expressed the following
fusion proteins: M–FKBP1 (labeled 1),
M–FKBP3 (2), M–FKBP1–Fas (3),
M–FKBP2–Fas (4), M–FKBP3–Fas (5),
DM–FKBP1–Fas (6), DM–FKBP3–Fas (7) and
M–Fas-cg–FKBP3 (8). The data were
normalized to the percentage of viable cells
from the untreated wells. The data shown in
(a–f) is representative of three separate
experiments, which are averaged in (g) along
with the results obtained with the additional
constructs. (h,i) Intracellular localization of
myristoylated M–FKBP–Fas (h) and non-
myristoylated DM–FKBP–Fas (i). Transiently-
transfected Jurkat-TAg cells were fixed and
stained with the anti-HA monoclonal antibody
12CA5; fluorescein-labeled rabbit anti-mouse
IgG was used as the secondary antibody.
Immunofluorescence was imaged by confocal
microscopy.
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To determine whether Fas-mediated signaling was devel-
opmentally restricted, overnight thymocyte cultures, incu-
bated with dilutions of FK1012, were stained and analyzed
for CD4 and CD8 expression, and for viability (Fig. 3).
Only double-positive thymocytes were sensitive to
FK1012-mediated cell ablation (Fig. 3d). Mature single-
positive CD4– CD8+ and CD4+ CD8– thymocytes (Fig.
3b,c, respectively) and immature double-negative thymo-
cytes (Fig. 3a) did not seem to be responsive to Fas signal-
ing. To rule out the formal possibility that only
double-positive thymocytes expressed the transgene,
single-positive CD4+ CD8– thymocytes were sorted by
FACS and analyzed for transgene expression by western
blotting (data not shown). Because expression of the trans-
gene was easily detectable in the CD4+ CD8– thymocytes
(albeit ~4-fold lower than double-positive expression), the
greatly reduced ability of Fas to signal apoptosis in single-
positive (CD4+) thymocytes cannot be explained simply by
a lack of transgene expression. Therefore, the signaling
pathway propagating Fas-mediated apoptosis seems to be
developmentally restricted. However, these experiments
do not rule out that very high levels of Fas signaling could
overcome the resistance of single-positive thymocytes to
Fas-mediated apoptosis.
FK1012 can efficiently trigger Fas-mediated apoptosis 
in vivo
Finally, we assessed the ability of FK1012 to trigger apop-
tosis in thymocytes in vivo by intravenous injection of
FK1012 (Fig. 4). One dose (~20 mg kg–1) of FK1012 was
administered to wild-type or transgenic mice (Fig. 4a,c,
respectively). Alternatively, carrier alone was injected into
control mice (Fig. 4b). The thymocyte subsets were ana-
lyzed ~16 hours later. Double-positive thymocytes were
almost completely eliminated (mean: ~83 % reduced) in
the treated transgenic mice relative to the mock-treated
transgenic mice (compare Fig. 4c with 4b); this result was
similar to that obtained in vitro. Concomitantly, there was a
commensurate increase in the proportion of other thymo-
cyte subsets. In contrast, there was a normal distribution of
subsets in the FK1012-treated, wild-type mice (Fig. 4a).
Repeated exposure to FK1012 had no detectable effect on
wild-type mice (data not shown). Although FK1012 did not
eliminate 100 % of double-positive thymocytes in vivo, the
normal influx and efflux of cells from the thymus probably
reduces the detectability of changes in double-positive
cells obtained with only one administration of FK1012,
which has a relatively short half life in plasma (less than
1 hour; data not shown). These experiments demonstrate,
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Figure 3
The effects of FK1012 on thymocyte subsets
in transgenic mice expressing M–FKBP2–Fas
from the Lck proximal promoter. (a–d)
Transgenic or wild-type thymocytes were
isolated and incubated for 20 h with complete
media containing various dilutions of
FK1012A. Cells were incubated with
CD4–FITC and CD8–PE antibodies and
analyzed by FACS for CD4 and CD8
expression and propidium iodide exclusion.
Gates were chosen to include the majority
(~95 %) of CD4– CD8– (a), CD4– CD8+ (b),
CD4+ CD8– (c), or CD4+ CD8+ (d)
thymocytes. The data represent the
percentage of total thymocytes within each
quadrant. There is typically ~20 % mortality of
double-positive thymocytes after overnight
culture.
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however, that chemical inducers of dimerization can condi-
tionally eliminate a lineage of cells in vivo.
Discussion
Dimerization is sufficient for Fas signaling
A variety of observations led to the expectation that dimer-
ization of Fas would be insufficient for signaling. Direct
biochemical data [24] and structural comparisons of FasL
with the highly homologous tumor necrosis factor a
(TNFa) [20] suggest that FasL is trimeric in solution.
TNFa is a homotrimer [30,31] and binds to TNFRI at a
ratio of 3:3 [32]. Furthermore, monoclonal antibodies that
trigger Fas-mediated cytolysis are either aggregates in solu-
tion (CH-11 is an IgM, APO-1 is from the self-associating
IgG3 class) or must be surface-bound [25,26]. Surprisingly,
however, we find that FK1012-mediated dimerization of
the death domain of Fas is sufficient for killing, albeit with
diminished potency relative to multimerization.
The sufficiency of dimerization is unlikely to be a general
artifact of this system because, as we have previously
shown, only two FKBPs can bind to one FK1012 molecule.
Furthermore, other signaling receptors, such as the z chain
of the T-cell receptor complex, clearly require multimer-
ization for signaling using the approach based on chemi-
cally induced dimerization [23]. Therefore, although
multimerization of the Fas receptor is the most efficient
pathway towards programmed cell death, dimerization of
the death domain is also capable of triggering apoptosis.
One potential reconciliation of these disparate results is
that dimerization mediated by intracellular dimerizing
agents can lead to, or augment, intermolecular aggrega-
tion of Fas receptors, leading to higher-order multimer-
ization than occurs with anti-Fas monoclonal antibody or
FasL. This possibility is consistent with recent reports
that the Fas and TNFRI death domains can self-aggre-
gate in vivo if highly overexpressed, leading to auto-sig-
naling and death ([33–35] and our unpublished
observations). If, however, aggregation occurs normally, it
must be via a weak interaction because anti-APO-1
F(ab′)2 fragments need to be further crosslinked to trigger
apoptosis [25]. Additionally, we saw no evidence that the
cytosolic Fas fusion protein, DM–FKBP1–Fas, interacted
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Figure 4
The effects of intravenous injection of FK1012
on thymocytes of transgenic mice expressing
M–FKBP2–Fas from the Lck proximal
promoter. (a–c) FACS analysis of thymocytes
from FK1012-treated (a,c) or mock-treated (b)
homozygous transgenic (b,c) or wild-type (a)
mice. Mice were injected intravenously with
40 ml of 10 mg ml–1 FK1012 and analyzed
16 h after injection. (a–c) are each
representative of three mice. (d) Bars
represent the percentage of cells falling within
each of the four distinct quadrants: FK1012-
treated wild-type mice (white); mock-treated
homozygous transgenic mice (grey); FK1012-
treated homozygous transgenic mice (black).
DP, double-positive; DN, double-negative. The
results of three mice per group are
represented.
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with endogenous membrane-bound Fas when the intra-
cellular localization of ectopically expressed Fas was
analyzed by confocal microscopy (Fig. 2i). Although the
possibility that a small number of undetected intracellular
aggregates can trigger apoptosis cannot be excluded,
these experiments demonstrate that the ligand that
triggers Fas-mediated apoptosis need not be a multimer.
This insight may have an important impact on the design
of Fas agonists and/or antagonists.
Membrane attachment is required for Fas-mediated
apoptosis in Jurkat cells
The use of intracellular dimerizing agents led to the
finding that cytosolic dimerization of Fas is insufficient to
signal apoptosis in Jurkat cells, suggesting that Fas proba-
bly functions as a scaffold for tethering FAPs to the
plasmid membrane. Additionally, this implies that the sub-
strates for FAPs are also membrane-localized. This hypoth-
esis seems at odds with published reports that merely
overexpressing the intracellular domain of Fas can be cyto-
toxic [34]. Although we saw a similar effect using the mem-
brane-tethered intracellular domain, M–Fas, or using
M–FKBPn–Fas, this cytotoxic effect was greatly reduced,
or absent, when the membrane attachment sequence was
removed (data not shown). It will be interesting to see
whether direct recruitment to the plasma membrane and
dimerization or oligomerization of other molecules that
contain death domains — such as FADD, TRADD and
RIP [6] — can bypass the need for Fas altogether.
Double-positive thymocytes are selectively Fas-sensitive
Although the Lck proximal promoter is active, and
chimeric Fas–FKBP is expressed throughout thymocyte
ontogeny, we found that only double-positive thymocytes
were sensitive to Fas-mediated killing in vitro. In homo-
zygous transgenic mice, a reduction of single-positive
thymocytes was seen only at the highest dose of FK1012
(1 mM), arguing that very high levels of Fas crosslinking
can partially overcome the refractory nature of single-posi-
tive thymocytes to Fas-mediated apoptosis (data not
shown). This is consistent with recent reports that single-
positive thymocytes express Fas; nevertheless, these cells
are still recalcitrant to Fas-mediated apoptosis ([19] and
our unpublished studies). Therefore, Fas expression is not
sufficient for Fas-mediated apoptosis in all cells.
FK1012 leads to apoptosis and rapid elimination of
Fas–FKBP-expressing thymocytes in vivo
A single intravenous injection of FK1012 led to the selec-
tive elimination of double-positive thymocytes in mice
expressing M–Fas–FKBP2 under the influence of the Lck
proximal promoter. Although another report had previ-
ously shown the preferential elimination of double-
positive thymocytes after injection of an anti-Fas
monoclonal antibody, this treatment led to a profound
fulminant hepatitis-like syndrome, and it could not be
ruled out that endogenous steroids or other stress-induced
serum factors were affecting thymocyte morbidity [19].
We found that the percentage of double-positive cells
decreased significantly (mean: ~83 % depletion), whereas
the proportional representation of the other major popula-
tions (that is, double-positive and single-positive cells)
experienced a commensurate increase. Interestingly, we
only saw a small increase (from ~3 % to ~20 %) in the
number of apoptotic cells in the thymus, as assayed by
propidium iodide uptake. The prompt disappearance of
apoptotic cells has been widely observed and probably
reflects the fact that most apoptotic cells are quickly
engulfed by phagocytic cells [36].
A role for Fas in thymic selection?
Whether or not Fas is involved in thymic selection
remains controversial. Clearly, Fas is not necessary for the
programmed cell death of the majority of double-positive
thymocytes, because negative selection and the size of the
thymus seem relatively normal in Fas-deficient mice [13].
If the role of Fas in thymocyte development can be substi-
tuted by one or more other proteins, such as the Fas
family member CD30, which is essential for at least some
negative selection [37], then an effect of Fas deficiency
might not be revealed without creating mice carrying
multiple deficiencies.
Conclusions
We have undertaken a novel approach to the study of
protein function by treating cells or transgenic animals
expressing rationally designed conditional alleles with low
molecular weight, synthetic molecules capable of inducing
dimerization. The current study investigated the mecha-
nisms of signaling mediated by the Fas receptor. With
these synthetic ligands we were able to trigger Fas-
mediated apoptosis efficiently at an LC50 as low as 10 nM
in vitro, and we ablated a T-cell lineage at a transient
concentration of 20 mg kg–1 in vivo.
Surprisingly, we find that the simple dimerization of two
Fas domains can trigger apoptosis. Because these reagents
permeate cells, we were able to study the role of mem-
brane attachment in Fas signaling, revealing that mem-
brane attachment is necessary for Fas-mediated apoptosis.
We were also able to study the ability of a conditional Fas
receptor to trigger apoptosis in transgenic mice. These
studies revealed that double-positive thymocytes are
particularly sensitive to Fas-mediated apoptosis. This
system should ultimately allow us to study the role of Fas
in a temporally controlled fashion in various tissues,
including its role in the B- and T-cell abnormalities of the
Fas-deficient mice and in autoimmunity. This technique
potentially allows for any dimerization-initiated signal to
be controlled in a tissue-specific fashion, and hence may
become a useful tool for the elucidation of signaling
events in developmental biology.
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Materials and methods
Cell culture
The murine T-cell line D10.11 [38] was grown in complete media
(RPMI 1040, 10 % fetal calf serum, 10 mM Hepes buffer (pH 7.4),
50 mM b-mercaptoethanol, penicillin (100 U ml–1), and streptomycin
(100 mg ml–1) containing 10–20 U ml–1 interleukin 2 (IL-2). Every
30 days the cells were restimulated with 10–20 × 106 irradiated
spleen cells from a C57BL/6 (I-Ab) mouse per 106 D10.11 cells.
Jurkat-TAg T cells [39] were grown in complete media without IL-2 and
b-mercaptoethanol.
Construction of chimeric receptors
The nucleotide sequence of the cytoplasmic domain of Fas was ampli-
fied by the polymerase chain reaction (PCR) from a Jurkat cDNA library
using 5′ primer 11610, 5′–cgacactcgag gta cag aaa aca tgc aga aag
c–3′, and 3′ primer 11611, 5′–cgtagagtcgac gac caa gct ttg gat ttc att
tc–3′. The primers contained XhoI and SalI restriction sites flanking
their 5′ and 3′ termini, respectively. The PCR product was subcloned
into the polylinker (XhoI and SalI digested) of pBluescript KSII+ (Strata-
gene) (pKS/Fas), sequenced and recloned into MF3E [23] (or a deriva-
tive) at the XhoI or SalI sites. To make Fas-cg, the fragment amplified
using primers 11611 and 12295, 5′–ggc ttt gtt cga aag aat ggt Aac
aat gaa gcc aaa ata g–3′ (mutation capitalized), was digested with
BstBI and SalI and subcloned into BstBI–SalI-digested pKS/Fas.
Transfections
Jurkat-TAg cells were transiently transfected in complete media as
described previously [23]. Briefly, 107 Jurkat-TAg cells were electropo-
rated with 4 mg of the various constructs using a Gene Pulser (BioRad)
at 250 V and 960 mF. After 5 min, cells (0.4 ml in a 0.4 cm cuvette) were
diluted into 10 ml complete media. D10.11 cells were transfected by a
similar protocol except that after 24 h we added 2 mg ml–1 G418 to
100 ml aliquots of transfected cells in complete media containing IL-2.
G418-resistant colonies were thereafter cloned by standard techniques.
DNA laddering assay
We treated 3 × 106 D10.11 cells (or subclones) for various times with
500 nM FK1012. After the incubations genomic DNA was prepared by
standard protocols. DNA pellets were resuspended in 20 ml TE and
separated on 1.8 % agarose gels containing 0.5 mg ml–1 ethidium
bromide.
FACS analysis and sorting
For thymocyte CD4 CD8 staining, approximately 2 × 106 thymocytes
were washed with staining media (PBS, 2 % calf serum) and resus-
pended in 30 ml staining media containing 1:100 dilutions of CD4–FITC
and CD8–PE (CALTAG Labs.). Cells were incubated in the dark for
20–30 min on ice and washed twice with staining media. Cells were
resuspended in 0.4 ml of staining media containing 1 mg ml–1 propidium
iodide and analyzed by FACS (FACScan-Becton Dickerson).
In order to enrich for transiently transfected Jurkat-TAg cells from the
bulk electropulsed population, 1 mg of pCA28D1 [40], which
expressed human CD8 without its cytoplasmic domain, was cotrans-
fected into Jurkat-TAg cells along with one of several Fas/FKBP con-
structs. After 24 h, transfected cells were stained with mouse
anti-human CD8–PE in 100 ml, diluted in buffer containing propidium
iodide, and isolated by FACS (Facstar). The brightest 50 000 cells
(~2–2.5 % total) were isolated, washed and further treated as
described.
Microscopy
Phase contrast microscopy was performed using a Zeiss Axiophot
microscope and Ektachrome 400 film. For fluorescence microscopy,
cells were prepared and stained as described previously [28] and
imaged by confocal microscopy (BioRad). Briefly, transfected cells
were settled for 10 min onto coverslips coated with 1 mg ml–1 poly-L-
lysine (Sigma P-2636) solution. Coverslips were rinsed in PBS and
treated for 10 min with 4 % paraformaldehyde in PBS at room tempera-
ture, washed twice with PBS, permeabilized with methanol for 2 min at
room temperature, and rinsed four times with PBS (or until all methanol
was removed). Permeabilized cells were incubated with primary anti-
body 12CA5 (~1 mg ml–1) in PBS containing 3 % BSA for 45 min at
room temperature, washed three times in PBS, incubated with FITC-
labeled secondary antibody (1:2000 of goat anti-mouse IgG (H + L),
Pharmingen) for 30 min at room temperature, and rinsed three times in
PBS. Lastly, coverslips/cells were mounted on a drop of 75 % glycerol,
containing 25 mM Tris–HCl (pH 8) and 0.1 % p-phenylenediamine.
Transgenic mice
The transgenic construct, Lckp-M/FKBP12/Fas/E was isolated as a
NotI fragment from the expression vector plck-HGH, and purified by
CsCl centrifugation. Mice were made by standard procedures. Trans-
genic mice were screened by the PCR from tail DNA using primers
#17851/Fas1(5′): 5′–cat gca gaa agc aca gaa agg aa–3′ and
#17852/hgh–3′: 5′–ggc gga gac tag cgt tgt caa–3′ giving an 880 bp
band. Transgene positive mice were assayed for protein expression by
western blotting of thymocyte extracts using 12CA5 as previously
described [23].
FK1012 was administered as a single intravenous injection. Briefly,
40 ml of 10 mg ml–1 FK1012 (in a solution containing a 1:1 ratio of
dimethylacetamide and 90 % PEG400/10 % TWEEN 80) was injected
under anesthesia (Metofane) into the retro-orbital sinus of mice aged
4–5 weeks. Approximately 16 h later, mice were euthanized by CO2
and analyzed.
Acknowledgements
We thank L. Holsinger, S. Morrison, E. Lagasse and L. Jerabek for technical
support and helpful discussions. The work was supported by HHMI grants
to G.R.C. and S.L.S, and NIH grants CA39612 and GM52067. P.J.B. was
supported by a fellowship from NSERC (3686).
References
1. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al.:
Monoclonal antibody-mediated tumor regression by induction of
apoptosis. Science 1989, 245:301–305.
2. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody
(anti-Fas) to a cell surface antigen co-downregulated with the
receptor of tumor necrosis factor. J Exp Med 1989,
169:1747–1756.
3. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M,
et al.: The polypeptide encoded by the cDNA for human cell
surface antigen Fas can mediate apoptosis. Cell 1991,
66:233–243.
4. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological
phenomenon with wide-ranging implications in tissue kinetics. Br
J Cancer 1972, 26:239–257.
5. Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of
cellular and viral proteins: activation, costimulation, and death.
Cell 1994, 76:959–962.
6. Cleveland JL, Ihle JN: Contenders in FasL/TNF death signaling. Cell
1995, 81:479–482.
7. Itoh N, Nagata S: A novel protein domain required for apoptosis.
Mutational analysis of human Fas antigen. J Biol Chem 1993,
268:10932–10937.
8. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV: A novel domain
within the 55 kd TNF receptor signals cell death. Cell 1993,
74:845–853.
9. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of
systemic autoimmunity and lymphoproliferative disease. Ann Rev
Immunol 1991, 9:243–269.
10. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer
A, de Villartay JP: Mutations in Fas associated with human
lymphoproliferative syndrome and autoimmunity. Science 1995,
268:1347–1349.
11. Matsuzawa A, Moriyama T, Kaneko T, Tanaka M, Kimura M, Ikeda H,
Katagiri T: A new allele of the lpr locus, lprcg, that complements
the gld gene in induction of lymphadenopathy in the mouse. J Exp
Med 1990, 171:519–531.
846 Current Biology 1996, Vol 6 No 7
12. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA,
Nagata S: Lymphoproliferation disorder in mice explained by
defects in Fas antigen that mediates apoptosis. Nature 1992,
356:314–317.
13. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N,
Nagata S: Targeted mutation in the Fas gene causes hyperplasia
in peripheral lymphoid organs and liver. Nat Genet 1995,
11:294–300.
14. Bossu P, Singer GG, Andres P, Ettinger R, Marshak-Rothstein A,
Abbas AK: Mature CD4+ T lymphocytes from MRL/lpr mice are
resistant to receptor-mediated tolerance and apoptosis. J
Immunol 1993, 151:7233–7239.
15. Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA: DNA
fragmentation and cell death is selectively triggered in activated
human lymphocytes by Fas antigen engagement. Cell Immunol
1992, 140:197–205.
16. Klas C, Debatin KM, Jonker RR, Krammer PH: Activation interferes
with the APO-1 pathway in mature human T cells. Int Immunol
1993, 5:625–630.
17. Strasser A: Death of a T cell. Nature 1995, 373:385–386.
18. Drappa J, Brot N, Elkon KB: The Fas protein is expressed at high
levels on CD4+CD8+ thymocytes and activated mature
lymphocytes in normal mice but not in the lupus-prone strain,
MRL lpr/lpr. Proc Natl Acad Sci USA 1993, 90:10340–10344.
19. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+
thymocytes by the anti-Fas antibody. J Exp Med 1995,
181:485–491.
20. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and
expression of the Fas ligand, a novel member of the tumor
necrosis factor family. Cell 1993, 75:1169–1178.
21. Steinberg AD, Roths JB, Murphy ED, Steinberg RT, Raveche ES:
Effects of thymectomy or androgen administration upon the
autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol 1980,
125:871–873.
22. Zhou T, Bluethmann H, Eldridge J, Berry K, Mountz JD: Origin of
CD4–CD8–B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell
receptor beta transgenic mouse. J Immunol 1993, 150:3651–3667.
23. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR: Controlling
signal transduction with synthetic ligands. Science 1993,
262:1019–1024.
24. Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the
functional soluble form of human Fas ligand in activated
lymphocytes. EMBO J 1995, 14:1129–1135.
25. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH:
Induction of apoptosis by monoclonal antibody anti-APO-1 class
switch variants is dependent on cross-linking of APO-1 cell
surface antigens. J Immunol 1992, 149:3166–3173.
26. Alderson MR, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley
K, Miller RE, Lynch DH: Regulation of apoptosis and T cell
activation by Fas-specific mAb. Int Immunol 1994, 6:1799–1806.
27. Cross FR, Garber EA, Pellman D, Hanafusa H: A short sequence in
the p60src N-terminus is required for p60src myristylation and
membrane association and for cell transformation. Mol Cell Biol
1994, 4:1834–1842.
28. Pruschy MN, Spencer DM, Kapoor TM, Miyake H, Crabtree GR,
Schreiber SL: Mechanistic studies of a signaling pathway
activated by the organic ligand FK1012. Chem & Biol 1994,
1:163–172.
29. Allen JM, Forbush KA, Perlmutter RM: Functional dissection of the
lck proximal promoter. Mol Cell Biol 1992, 12:2758–2768.
30. Smith RA, Baglioni C: The active form of tumor necrosis factor is a
trimer. J Biol Chem 1987, 262:6951–6954.
31. Jones EY, Stuart DI, Walker NP: Structure of tumour necrosis
factor. Nature 1989, 338:225–228.
32. Banner DW, D’Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C,
et al.: Crystal structure of the soluble human 55 kd TNF receptor-
human TNF beta complex: implications for TNF receptor
activation. Cell 1993, 73:431–445.
33. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach
D: A novel protein that interacts with the death domain of
Fas/APO1 contains a sequence motif related to the death
domain. J Biol Chem 1995, 270:7795–7798.
34. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y,
Camonis JH, Wallach D: Self-association of the ‘death domains’ of
the p55 tumor necrosis factor (TNF) receptor and Fas/APO1
prompts signaling for TNF and Fas/APO1 effects. J Biol Chem
1995, 270:387–391.
35. Song HY, Dunbar JD, Donner DB: Aggregation of the intracellular
domain of the type 1 tumor necrosis factor receptor defined by
the two-hybrid system. J Biol Chem 1994, 269:22492–22495.
36. Surh CD, Sprent J: T-cell apoptosis detected in situ during positive
and negative selection in the thymus. Nature 1994, 372:100–103.
37. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E,
et al.: Impaired negative selection of T cells in Hodgkin’s disease
antigen CD30-deficient mice. Cell 1996, 84:551–562.
38. Kaye J, Porcelli S, Tite J, Jones B, Janeway CAJ: Both a monoclonal
antibody and antisera specific for determinants unique to
individual cloned helper T cell lines can substitute for antigen and
antigen-presenting cells in the activation of T cells. J Exp Med
1983, 158:836–856.
39. Northrop JP, Ullman KS, Crabtree GR: Characterization of the
nuclear and cytoplasmic components of the lymphoid-specific
nuclear factor of activated T cells (NF-AT) complex. J Biol Chem
1993, 268:2917–2923.
40. Crooks ME, Littman DR, Carter RH, Fearon DT, Weiss A, Stein PH:
CD28-mediated costimulation in the absence of
phosphatidylinositol 3-kinase association and activation. Mol Cell
Biol 1995, 15:6820–6828.
Research Paper  Conditional Fas signaling Spencer et al. 847
